Sign In
Buy ROIV
$31.25
-0.180 (-0.573%)
At Close: Jun 22, 2026
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced
07:28am, Thursday, 13'th Nov 2025
ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease dru
Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
10:31am, Tuesday, 11'th Nov 2025
Roivant Sciences Ltd. ( ROIV ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST Company Participants Richard Pulik - Chief Financial Officer Conference C
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
12:31pm, Monday, 10'th Nov 2025
Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Direc
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
09:25am, Monday, 10'th Nov 2025
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27.
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
07:00am, Monday, 10'th Nov 2025
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Nov
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
02:47am, Thursday, 25'th Sep 2025
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript
10:57pm, Wednesday, 24'th Sep 2025
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants J
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd.
01:01pm, Tuesday, 23'rd Sep 2025
Does Roivant Sciences Ltd. (ROIV) have what it takes to be a top stock pick for momentum investors?
Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript
05:45am, Tuesday, 23'rd Sep 2025
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
11:36am, Thursday, 18'th Sep 2025
Montes Archimedes Acquisition (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furt
Roivant Sciences Ltd. - Special Call
03:43pm, Wednesday, 17'th Sep 2025
Roivant Sciences Ltd. - Special Call Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer Conference Call Participan
Why Roivant Sciences Stock Is Soaring Today
12:49pm, Wednesday, 17'th Sep 2025
Shares of Roivant Sciences (ROIV 12.14%) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday.
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
12:13pm, Wednesday, 17'th Sep 2025
Roivant Sciences Ltd ROIV and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).
